# Assessment of Genomic Test Impact on Shared Decision of Adjuvant Chemotherapy in ER-positive, Her2-negative Early Breast Cancer

> **NCT03080428** · NA · WITHDRAWN · sponsor: **UNICANCER**

## Conditions studied

- ER-positive Her2-negative Early Breast Cancer

## Interventions

- **DIAGNOSTIC_TEST:** Genomic test

## Key facts

- **NCT ID:** NCT03080428
- **Lead sponsor:** UNICANCER
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2017-05
- **Primary completion:** 2018-06
- **Final completion:** 2023-05
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** The study has been withdrawn because of lack of funding
- **Last updated:** 2017-08-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03080428

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03080428, "Assessment of Genomic Test Impact on Shared Decision of Adjuvant Chemotherapy in ER-positive, Her2-negative Early Breast Cancer". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT03080428. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*